Transforming growth factor-beta as a treatment target in renal diseases.
Transforming growth factor-beta as a treatment target in renal diseases.
复制标题
DOI：
--
复制
发表时间：
2009-11
影响因子：
3.4
通讯作者：
N. Fukuda;Y. Tahira;H. Matsuda;Koichi Matsumoto
中科院分区：
文献类型：
--
作者：
N. Fukuda;Y. Tahira;H. Matsuda;Koichi Matsumoto
许多研究已确定转化生长因子-β (TGF-β) 是肾小球硬化和系膜增生性肾小球肾炎等肾脏疾病的关键因素。 TGF-β刺激肾小球系膜细胞增殖、细胞外基质成分产生并诱导肾组织上皮间质转化，在肾损伤的发病机制中发挥着关键作用。因此，TGF-β是肾脏疾病的治疗靶点。然而，目前的医疗技术无法治愈进行性肾脏疾病。我们开发了核酶和一种针对 TGF-β 的新型基因沉默剂吡咯咪唑聚酰胺，可有效改善高血压大鼠的肾损伤。
A number of studies have identified transforming growth factor-beta (TGF-beta) as a critical factor in renal diseases such as glomerulosclerosis and mesangioproliferative glomerulonephritis. TGF-beta stimulates proliferation of mesangial cells, production of extracellular matrix components and induces epithelial-mesenchymal transformation in renal tissue, which plays a critical role in the pathogenesis of renal injury. Thus, TGF-beta is a treatment target in renal diseases. However, progressive renal diseases cannot be cured with present medical technologies. We have developed ribozymes and a novel gene silencer pyrrole-imidazole polyamide targeted to TGF-beta that effectively ameliorate renal injury in hypertensive rats.